This page contains a Flash digital edition of a book.
Beyond fit for purpose. Assay precision today gives you confidence for the next phase.


You don’t know what the future holds.


Be ready for the next step with biomarker assays that are beyond fit-for-purpose.


Get the same reproducibility and high degree of analytical validation, no matter which of our assay platforms you choose: • Ultrasensitive Singulex Erenna® assays • High-precision GyroMark™ HT kits • Robust ELISAs • Rich profiling data from MILLIPLEX® panels for the Luminex® platform


We help you get data you trust out of each sample, with minimal repetition, so you can make the best next-step decisions.


EMD Millipore Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany


EMD Millipore and the M logo and MILLIPLEX are registered trademarks of Merck KGaA, Darmstadt, Germany. GyroMark is a trademark of Merck KGaA, Darmstadt, Germany. All other trademarks belonging to third parties are the properties of their respective owners. BS-GEN-16-122254 © 2016 EMD Millipore Corporation, Billerica, MA USA. All rights reserved.


IL-6 PBMC Sample Correlation


1,000 1,200 1,400 1,600


800


600 400


0 50 100 150 200 250 300 350 400 450 500 ELISA (pg/mL)


PBMC sample correlation for IL-6 between the MILLIPLEX® MAP Human Cytokine/Chemokine Magnetic Bead Panel and the individual cytokine ELISA.


Download our Analyte Quarterly brochure to start building your scientific success. www.emdmillipore.com/biomarkerassays


y= 1.9849x + 503.88 R= 0.989


MILLIPLEX® MAP assay (pg/mL)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54